The use of omega-3 fatty acids in mental illness

Journal of Pharmacy Practice

Volumn 24, Issue 5, 2011, Pages 452-471

  Gören, Jessica L ^a,b,c   Tewksbury, Ashley T ^c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b CAMBRIDGE HEALTH ALLIANCE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

fatty acids; mental illness; omega 3; omega 6; polyunsaturated

Indexed keywords

CLOZAPINE; DOCOSAHEXAENOIC ACID; FLUOXETINE; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

AFFECTIVE PSYCHOSIS; ANXIETY DISORDER; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; DEPRESSION; DIETARY INTAKE; DRUG EFFECT; FISH; HAMILTON SCALE; HUMAN; INTELLIGENCE QUOTIENT; MAJOR DEPRESSION; MEDLINE; MENTAL DISEASE; MOOD DISORDER; PERSONALITY DISORDER; PSYCHOSIS; PUERPERAL DEPRESSION; SCHIZOPHRENIA; SEA FOOD; SUBSTANCE ABUSE; TREATMENT OUTCOME;

EID: 83455245796     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190011422876     Document Type: Article

References (167)

1. Calder PC, Yaqoob PY. Understanding omega-3 polyunsaturated fatty acids. Postgrad Med. 2009 ; 121 (6). 148-157
2. Kidd PM. Omega-3 DHA and EPA for cognitive, behavior, and mood: clinical findings and structural functional synergies with cell membrane phospholipids. Alt Med Rev. 2007 ; 12 (3). 207-227 (Pubitemid 47613220)
3. Heinrichs SC. Dietary omega-3 fatty acid supplementation for optimizing neuronal structure. Mol Nutr Food Res. 2010 ; 54: 447-456
4. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 2003 ; 278 (44). 43807-43817 (Pubitemid 37346009)
5. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002 ; 196 (8). 1025-1037 (Pubitemid 35231761)
6. Hong S, Gronert K, Devchand PR, et al. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem. 2003 ; 278 (17). 14677-14687 (Pubitemid 36799790)
7. Cade J, Thomas E, Vail A. Case-control study of breast cancer in south east England: nutritional factors. J Epidemiol Comm Health. 1998 ; 52 (2). 105-110 (Pubitemid 28056822)
8. Lauritzen L, Hansen HS, Jorgensen MH, et al. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res. 2001 ; 40 (12). 1-94 (Pubitemid 32008650)
9. Niu SL, Mitchell DC, Lim SY, et al. Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency. J Biol Chem. 2004 ; 279 (30). 31098-31104 (Pubitemid 39037771)
10. Hirashima F, Parow AM, Stoll AL, et al. Omega-3 fatty acid treatment and T2 whole brain relaxation times in bipolar disorder. Am J Psychiatry. 2004 ; 161: 1922-1924 (Pubitemid 39314692)
11. McVeigh GE, Brennan Cohn JN, et al. N-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. Am J Clin Nutr. 1997 ; 65: 459-464
12. Chin JP, Dart PY. How do fish oils affect vascular function?. Clin Exp Pharmacol Physiol. 1995 ; 22: 71-81
13. TEritslad J, Arnesen H, Gronseth K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996 ; 77: 31-36 (Pubitemid 26018387)
14. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arteroiscler Thromb Vasc Biol. 1998 ; 18: 723-731 (Pubitemid 28267651)
15. Kang JX, Leaf A. Antiarrythmic effects of polyunsaturated fatty acids: recent studies. Circulation. 1996 ; 94: 1774-1780 (Pubitemid 26320288)
16. Kris-Etherton PM, Harris WS, Appel LJ. for the nutrition committee. AHA scientific statement on fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002 ; 106: 2747-2757
17. Holub DJ, Holub PY. Omega-3 fatty acids from fish oils and cardiovascular disease. Mol Cell Biochem. 2004 ; 263: 217-225 (Pubitemid 39256160)
18. Office of Nutritional Products, Labeling, and Dietary Supplements, Center for Food Safety and Applied Nutrition, US Food and Drug Administration. Letter responding to a request to reconsider the qualified health claim for a dietary supplement health clain for omega-3 fatty acids and coronary heart disease. http://www.fda.gov/SiteIndex/ucm072932.htm. Accessed June 21, 2011.
19. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006 ; 67: 1954-1967 (Pubitemid 46048194)
20. Timonen M, Horrobin D, Jokelainen J, et al. Fish consumption and depression: the northern Finland 1996 birth cohort. J Affect Disord. 2004 ; 82: 447-452 (Pubitemid 39536178)
21. Lin PY, Huang SY, Su PY. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry. 2010 ; 68: 140-147
22. Tiemeier H, van Tuijil HR, Kiliaan AJ, et al. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam study. Am J Clin Nutr. 2003 ; 78: 40-46 (Pubitemid 39655246)
23. Sublette ME, Segal-Isaacson CJ, Cooper TB, et al. Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am J Psychiatry. 2006 ; 163 (6). 1100-1102 (Pubitemid 44464499)
24. Tanskanen A, Hibbeln JR, Tuomilehto J, et al. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv. 2001 ; 52: 529-531 (Pubitemid 32275317)
25. Maes M, Smith R, Christophe A, et al. Fatty acid composition in major depression: decreased omega-3 fractions in cholesteryl esters and increased C20:4 omega-6/C20:5 omega-3 ration in cholesteryl esters and phospholipids. J Affect Disord. 1996 ; 38: 35-46
26. Adams PB, Lawson S, Sanigorski A, et al. Arachidonic acid to eisocapentaenoic acid correlates positively with clinical symptoms of depression. Lipids. 1996 ; (suppl). S157 - S161
27. Peet M, Murphy B, Shay J, et al. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998 ; 43: 315-319 (Pubitemid 28137622)
28. Murakami K, Miyake Y, Sasaki S, et al. Fish and n-3 polyunsaturated fatty acid intake and depressive symptoms: Ryukyus child health study. Pediatrics. 2010 ; 126 (3). e623 - e630
29. Hakkarainen R, Partonen T, Haukka J, et al. Is low dietary intake of omega-3 fatty acids associated with depression?. Am J Psychiatry. 2004 ; 161: 567-569 (Pubitemid 38326115)
30. Bot A, Pouwer F, Assies J, et al. Eicosapentaenoic acid as an add on to antidepressant medication for comorbid major depression in patients with diabetes mellitus: a randomized, double blind, placebo controlled study. J Affect Disord. 2010 ; 126: 282-286
31. Carney RM, Freedland KE, Rubin EH, et al. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA. 2009 ; 302 (15). 1651-1657
32. Grenyer BF, Crowe T, Owen AJ, et al. Fish oil supplementation in the treatment of major depression: a randomized double blind placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007 ; 31 (7). 1393-1396 (Pubitemid 47304478)
33. Nemets B, Stahl Z, Belmaker PY. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depression. Am J Psychiatry. 2002 ; 159 (3). 477-479 (Pubitemid 34184747)
34. Peet M, Horrobin PY. A dose ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002 ; 59 (10). 913-919
35. Silvers KM, Woolley CC, Hamilton FC, et al. Randomized double blind placebo controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids. 2005 ; 72 (3). 211-218 (Pubitemid 40139086)
36. Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder: a preliminary double blind, placebo controlled trial. Eur Neuropsychopharmacol. 2003 ; 13 (4). 267-271
37. Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: a controlled double blind pilot study. Am J Psychiatry. 2006 ; 163 (6). 1098-1100 (Pubitemid 44464498)
38. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination in major depressive disorder. Aust N Z J Psychiatry. 2008 ; 42 (3). 192-198 (Pubitemid 351234188)
39. Lucas M, Asselin G, Merette C, et al. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double blind placebo controlled randomized trial. Am J Clin Nutr. 2009 ; 89 (2). 641-651
40. Marangell LB, Martinez JM, Zboyan HA, et al. A double blind placebo controlled study o f the omega-3 fatty acid docosahexaenoic acid in the treatment o f major depression. Am J Psychiatry. 2003 ; 160: 996-998 (Pubitemid 41079588)
41. Mischoulon D, Papakostas GI, Dording CM, et al. A double blind randomized controlled trial of ethyl-eicosapentaenoate for major depression. J Clin Psychiatry. 2009 ; 70 (12). 1363-1644
42. Mischoulon D, Best-Popescu C, Laposata M, et al. A double blind dose finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008 ; 18 (9). 639-645
43. Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomized controlled trial. Br J Nutr. 2008 ; 99: 421-431
44. Rondanelli M, Giacosa A, Opizzi A, et al. Effects of omega-3 fatty acids supplementation on depressive symptoms and on health related quality of life in treatment of elderly women with depression: a double blind placebo controlled randomized trial. J Am Coll Nutr. 2010 ; 29 (1). 55-64
45. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil supplementation on mental well being in older subjects: a randomized double blind placebo controlled trial. Am J Clin Nutr. 2008 ; 88: 706-713
46. Martin JG. EPA but not DHA appears responsible to for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta analysis of randomized controlled trials. J Am Coll Nutr. 2009 ; 28 (5). 525-542
47. Innis SM. Perinatal biochemistry and physiology of long chain polyunsaturated fats. Pediatrics. 2003 ; 143 (4 suppl). S1 - S8
48. Hibbeln JR, Davis PY. Considerations regarding neuropsychiatric nutritional requirements for intakes of omega-3 highly unsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2009 ; 81: 179-186
49. Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression. J Affect Disord. 2002 ; 69: 15-29 (Pubitemid 34722867)
50. Sontrop J, Campbell PY. Omega-3 polyunsaturated fatty acids and depression: a review of the evidence and methodological critique. Prev Med. 2006 ; 42: 4-13 (Pubitemid 43148942)
51. Brown JC, Scott KM, Silvers PY. Fish consumption and omega-3 status after birth are not associated with post natal depression. J Affect Disord. 2006 ; 90 (2-3). 1310139
52. Miyake Y, Sasaki S, Yokoyama T, et al. Risk of postpartum depression in relation to dietary fish intake and fat intake in Japan: the Osaka maternal and child health study. Psychol Med. 2006 ; 36 (12). 1727-1735 (Pubitemid 44824734)
53. Strom M, Mortensen EL, Halldorsson TI, et al. Fish and long chain n-3 polyunsaturated fatty acid intakes during pregnancy and risk of postpartum depression: a prospective study based on a large national birth cohort. Am J Clin Nutr. 2009 ; 90: 149-155
54. Hibbeln JR, Davis JM, Steer C, et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet. 2007 ; 369: 578-585 (Pubitemid 46241443)
55. Otto SJ, de Groot RH, Hornstra G. Increased postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic acid status. Prstaglandins Leukot Essent Fatty Acids. 2003 ; 69: 237-243 (Pubitemid 37463804)
56. Doornbos B, van Goor SA, Dijick-Brouwer DAJ, et al. Supplementation of a low dose of DHA or DHA + AA does not prevent peripartum depressive symptoms in a small population based sample. Prog Neuropsychopharmacol. 2009 ; 33: 49-52
57. Freeman MP, Hibbeln JR, Wisner KL, et al. Randomized dose ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatry Scand. 2006 ; 113 (1). 31-35 (Pubitemid 43339086)
58. Freeman MP, Davis M, Sinha P, et al. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo controlled study. J Affect Disord. 2008 ; 110 (1-2). 142-148
59. Llorente AM, Jensen CL, Voigy RG, et al. Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol. 2003 ; 188 (5). 1348-1353 (Pubitemid 36589134)
60. Makrides M, Gibsom RA, McPhee AJ, et al. and DOMInO Investigative Team. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children. JAMA. 2010 ; 304 (15). 1675-1683
61. Rees AM, Austin MO, Parker PY. Omega-3 fatty acids as a treatment for perinatal depression: randomized double blind placebo controlled trial. Aust Z J Psychiatry. 2008 ; 42 (3). 199-205
62. Rao JS, Rapoport PY. Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol. 2009 ; 2 (2). 207-214
63. Chen CT, Green JT, Orr SK, et al. Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukotr Essent Fatty Acids. 2008 ; 79: 85-91
64. Naoghiul S, Hibbeln PY. Cross-national comparisons of seafood consumption and rates of bipolar disorder. Am J Psychiatry. 2003 ; 160 (12). 2222-2227
65. Chiu CC, Huang SY, Su KP, et al. Polyunsaturated fatty acid deficits in patients with bipolar mania. Eur Neuropsychopharmacol. 2003 ; 13: 99-103
66. Ranjekar PK, Hinge A, Hedge MV, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatr Res. 2003 ; 121: 109-122 (Pubitemid 37500981)
67. Igarashi M, Ma K, Gao F, et al. Brain lipid concentrations in bipolar disorder. J Psychiatr Res. 2010 ; 43 (3). 177-186
68. Clayton EH, Hanstock TL, Hirneth SJ, et al. Long chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder. Lipids. 2008 ; 43: 1031-1038
69. Clayton EH, Hanstock TL, Hirneth SJ, et al. Reduced mania and depression in juvenile bipolar disorder associated with long chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr. 2009 ; 63: 1037-1040
70. Sublette ME, Bosetti F, DeMar JC, et al. Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disor. 2007 ; 9 (7). 759-765 (Pubitemid 350042412)
71. Chiu CC, Huang SY, Chen CC, et al. Omega-3 fatty acids are more beneficial in the depressive phase than the manic phase in patients with bipolar I disorder. J Clin Psychiatry. 2005 ; 66 (12). 1613-1614
72. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomized double blind placebo controlled study. Br J Psychiatry. 2006 ; 75 (4-5). 315-312
73. Keck PE, Mintz J, McElroy SL, et al. Double blind randomized placebo controlled trials of ethyl-eicosapentaenoate in the treatment of bipolar depression and rapid cycling bipolar disorders. Biol Psychiatry. 2006 ; 60 (9). 1020-1022 (Pubitemid 44739928)
74. Osher Y, Bersudsky Y, Belmaker PY. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open label study. J Clin Psychiatry. 2005 ; 66 (6). 726-729 (Pubitemid 40942418)
75. Marrangell LB, Suppes T, Ketter TA, et al. Omega-3 fatty acids in bipolar disorder: clinical and research considerations. Prostaglandins Leukot Essent Fatty Acids. 2006 ; 75 (4-5). 315-321 (Pubitemid 44442915)
76. Stoll Al, Severus WE, Freeman MP, et al. Omega-3 fatty acids in bipolar disorder. Arch Gen Psychiatry. 1999 ; 56 (5). 407-412
77. Gracious BL, Chirieac MC, Costescu S, et al. Randomized placebo controlled trial of flax oil in pediatric depression. Bipolar Disord. 2010 ; 12: 142-154
78. Wozniak J, Biederman J, Mick E, et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open label trial. Eur Neuropsychopharmacol. 2007 ; 17 (6-7). 440-447 (Pubitemid 46497662)
79. Emsley R, Oosthuizen P, van Rensburh SJ. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs. 2003 ; 17 (15). 1081-1091 (Pubitemid 38021394)
80. Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res. 1994 ; 13 (3). 195-201
81. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry. 2000 ; 47 (1). 8-21 (Pubitemid 30016075)
82. Piomelli D, Pilon C, Giros B, et al. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature. 1991 ; 353 (6340). 164-167 (Pubitemid 21912481)
83. Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A. 2007 ; 104 (42). 16621-16626 (Pubitemid 350211066)
84. Prabakaran S, Swatton JE, Ryan MM, et al. Mitochondrial dysfunction in schizophrenia: evidence of compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004 ; 9 (7). 684-697 (Pubitemid 38932173)
85. Peet M, Laugharne J, Rangarajan N, et al. Depleted red blood cell membrane essential fatty acids in drug treated schizophrenics. J Psychiatr Res. 1995 ; 29 (3). 227-232
86. Mahadik SP, Mukherjee S, Horrobin DF, et al. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar and normal subjects. Psychiatr Res. 1996 ; 63 (2-3). 133-142 (Pubitemid 26276604)
87. Assies J, Lieverse R, Vreken P, et al. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry. 2001 ; 49: 510-520
88. Vaddadi KS, Gilleard CJ, Soosai E, et al. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophr Res. 1996 ; 20 (3). 287-294 (Pubitemid 26232973)
89. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices. Br J Psychiatry. 2004 ; 184: 404-408 (Pubitemid 38624766)
90. Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand. 1988 ; 78 (5). 587-591
91. Hedelin M, Lof M, Olsson M, et al. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population. BMC Psychiatry. 2010 ; 10: 38
92. Sinclair HM. Deficiencies of essential fatty acids and atherosclerosis et cetera. Lancet. 1956 ; 1: 381-383
93. Amminger GP, Schafer MR, Papageorgiou K, et al. Long chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized placebo controlled trial. Arch Gen Psychiatry. 2010 ; 67 (2). 146-154
94. Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double blind clinical trial results. Prostaglandins Leukot Essent Fatty Acids. 2003 ; 69 (6). 477-485 (Pubitemid 37464058)
95. Arvindakshan M, Ghate M, Ranjekar PK, et al. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome in schizophrenia. Schizophr Res. 2003 ; 62: 195-204 (Pubitemid 36773928)
96. Berger GE, Proffitt TM, McConchie M, et al. Ethyl-eicosapentaenoic acid in first episode psychosis a randomized placebo controlled trial. J Clin Psychiatry. 2007 ; 68 (12). 1867-1875
97. Emsley R, Myburgh C, Oosthuizen P, et al. Randomized placebo controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry. 2002 ; 159 (9). 1596-1598 (Pubitemid 35006744)
98. Fenton WS, Dickerson F, Boronow J, et al. A placebo controlled trial of omega-3 fatty acid (ethyl-eicospentaenoic acid) supplement for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001 ; 158: 2071-2074 (Pubitemid 33104119)
99. Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001 ; 49 (3). 243-251 (Pubitemid 32453225)
100. Peet M, Horrobin DF. A dose ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002 ; 36 (1). 7-18 (Pubitemid 34037843)
101. Emsley R, Niehaus DJ, Koen L, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized placebo controlled trial. Schizophr Res. 2006 ; 84 (1). 112-120 (Pubitemid 44255716)
102. Emsley R, Niehaus DJ, Oosthuizen PP, et al. Safety of omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized placebo controlled trial. Psychiatr Res. 2008 ; 161 (3). 284-291
103. Wolkin A, Jordan B, Peselow E, et al. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry. 1986 ; 143 (7). 912-914 (Pubitemid 16090404)
104. McNamara RK, Able J, Jandacek R, et al. Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo controlled, dose ranging, functional magnetic resonance imaging study. Am J Clin Nutr. 2010 ; 91: 1060-1067
105. Hibbeln JR, Davis JM, Steer C, et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet. 2007 ; 369: 578-585 (Pubitemid 46241443)
106. Raz R, Gabis L. Essential fatty acids and attention deficit hyperactivity disorder: a systematic review. Dev Med Chil Neurol. 2009 ; 51: 580-592
107. Antalis CJ, Stevens LJ, Campbell M, et al. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2006 ; 75 (4-5). 299-308 (Pubitemid 44442911)
108. Kidd PM. Omega-3 DHA and EPA for cognitive, behavior, and mood: clinical findings and structural functional synergies with cell membrane phospholipids. Alt Med Rev. 2007 ; 12 (3). 207-227 (Pubitemid 47613220)
109. Stevens LJ, Zentall SS, Abate ML, et al. Omega-3 fatty acids in boys with behavior, learning and health problems. Physiol Behav. 1996 ; 59: 915-920 (Pubitemid 26110718)
110. Young GS, Maharaj NJ, Conquer PY. Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids. 2004 ; 39 (2). 117-123 (Pubitemid 38480941)
111. Aman MG, Mitchell EA, Turbott PY. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J Abnorm Child Psychol. 1987 ; 15: 75-90 (Pubitemid 17039438)
112. Arnold LE, Kley-Kamp D, Votolato MA, et al. Gamma linolenic acid for attention deficit hyperactivity disorder: placebo controlled comparison to d-amphetamine. Biol Psychiatry. 1989 ; 25 (2). 222-228 (Pubitemid 19034959)
113. Brue AW, Oakland TD, Evans PY. The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Sci Rev Altern Med. 2001 ; 5 (4). 187-194 (Pubitemid 34464143)
114. Harding KL, Judah RD, Gant C. Outcomes based comparison of Ritalin versus food supplement treated children with AD/HD. Altern Med Rev. 2003 ; 8: 319-330 (Pubitemid 37099890)
115. Hirayama S, Hamazaki T, Terasawa K. Effects of docosahexaenoic acid containing food administration on symptoms of attention deficit/hyperactivity disorder: placebo controlled double blind study. Eur J Nutr. 2004 ; 58: 467-473
116. Itomura M, Hamazaki K, Sawazaki S, et al. The effect of fish oil on physical aggression in school children: a randomized double blind placebo controlled trial. J Nutr Biochem. 2005 ; 16 (3). 163-171 (Pubitemid 40312169)
117. Johnson M, Ostlund S, Fransson G, et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo controlled trial in children and adolescents. J Affect Disord. 2009 ; 12 (5). 394-401
118. Raz R, Carasso RL, Yehuda S. The influence of short chain essential fatty acids on children with attention deficit/hyperactivity disorder: a randomized placebo controlled study. J Child Adolesc Psychopharmacol. 2009 ; 19: 167-177
119. Richardson AJ, Montgomery P. The Oxford-Durham study: a randomized controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics. 2005 ; 115: 1360-1366 (Pubitemid 43843244)
120. Richardson AJ, Puri PY. A randomized double blind placebo controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning disabilities. Prog Neuropsychopharmacol Biol Psychiatry. 2002 ; 26: 233-239 (Pubitemid 34038049)
121. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with childhood ADHD. J Dev Behav Pediatr. 2007 ; 28: 82-91 (Pubitemid 46624832)
122. Stevens L, Zhang W, Peck L, et al. EFA supplementation in children with inattention, hyperactivity and other disruptive behaviors. Lipids. 2003 ; 38 (10). 1007-1021 (Pubitemid 37444624)
123. Voigt RG, Llorente AM, Jensen CL, et al. A randomized double blind placebo controlled trial of docosahexaenoic acid supplementation in children with attention deficit/hyperactivity disorder. J Pediatr. 2001 ; 139 (2). 189-196 (Pubitemid 32721703)
124. Vaisman N, Kaysar N, Zaruk-Adasha Y, et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr. 2008 ; 87 (5). 1170-1180 (Pubitemid 351679755)
125. Antalis CJ, Stevens LJ, Campbell M, et al. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Protaglandin Leukot Essent Fatty Acids. 2006 ; 75 (4-5). 299-308 (Pubitemid 44442911)
126. Sander JL. Qualitative differences between Asperger's disorder and autism? Historical considerations. J Autism Dev Disord. 2009 ; 39 (11). 1560-1567
127. National Institute of Health (2010). Autism Spectrum Disorders. http://www.nichd.nih.gov/health/topics/asd.cfm. Accessed January 25, 2010.
128. Ozonoff S, Iosif A, Baguio F, et al. A prospective study of the emergence of early behavioral signs of autism. J Am Acad Child Adolesc Psychiatry. 2010 ; 49 (3). 256-266
129. Mandell DS, Novak MM, Zubritsky PY. Factors associated with age of diagnosis with autism spectrum disorders. Pediatrics. 2005 ; 116 (5). 1480-1486 (Pubitemid 46056498)
130. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004 ; 80 (6). 1611-1617 (Pubitemid 41103861)
131. Ross MA. Could oxidative stress be a factor in neurodevelopmental disorders?. Prostaglandin Leukot Essent Fatty Acids. 2000 ; 63: 61-64
132. Malik M, Sheikh AM, Wen G, et al. Expression of inflammatory cytokines, Bcl2 and cathepsin D are altered in lymphoblast of autistic subjects. Immunobiology. 2011 ; 216 (1-2). 80-85
133. Kim HY, Akbar M, Kim PY. Inhibition of neuronal apoptosis by polyunsaturated fatty acids. J Mol Neurosci. 2001 ; 16 (2-3). 223-227 (Pubitemid 32664783)
134. Kim HY, Akbar M, Lau A. Effects of docosapentaenoic acid on neuronal apoptosis. Lipids. 2003 ; 38 (4). 453-457 (Pubitemid 36724305)
135. Orr SK, Bazinet PY. The emerging role of docosahexaenoic acid in neuroinflammation. Curr Opin Investig Drugs. 2008 ; 9 (7). 735-743 (Pubitemid 351950870)
136. Ahmad SO, Park JH, Radel JD, et al. Reduced numbers of dopamine neurons in the substantia nigra pars compacta and ventral segmental area of rats fed an omega-3 polyunsaturated fatty acid-deficient diet: a stereological study. Neurosci Lett. 2008 ; 438 (3). 3030-3307
137. Wainwright PE. Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proc Nutr Soc. 2002 ; 61: 61-69 (Pubitemid 34171047)
138. Kootz JP, Marinelli B, Cohen PY. Modulation of response to environmental stimulation in autistic children. J Autism Dev Disord. 1982 ; 12 (2). 185-193 (Pubitemid 12018686)
139. Clark T, Feehan C, Tinline C. Autistic symptoms in children with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry. 1999 ; 8 (1). 50-55 (Pubitemid 29222751)
140. Ponde MP, Novaes CM, Losapio PY. Frequency of symptoms of attention deficit and hyperactivity disorder in autistic children. Arq Neuropsiquiatr. 2010 ; 68 (1). 103-106
141. Ronald A, Simonoff E, Kuntsi J, et al. Evidence for overlapping genetic influences on autistic and ADHD behaviors in a community twin sample. J Child Psychol Psychiatry. 2008 ; 49: 535-542 (Pubitemid 351503093)
142. Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids. 2001 ; 65 (1). 1-7 (Pubitemid 32783435)
143. Wiest MM, German JB, Harvey PY. Plasma fatty acid profiles in autism: a case-control study. Prostaglandins Leukot Essent Fatty Acids. 2009 ; 80 (4). 221-227
144. Sliwinski S, Croonenberghs J, Christophe A, et al. Polyunsaturated fatty acids: do they have a role in the pathophysiology of autism?. Neuroendocrinol Lett. 2006 ; 27 (4). 465-471 (Pubitemid 46043603)
145. McNamara R, Jandacek R, Rider T, et al. Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats. Eur J Pharmacol. 2011 ; 652 (1-3). 152-156
146. McNamara R, Able J, Jandacek R, et al. Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis. Schizophr Res. 2009 ; 107 (2-3). 150-157
147. Gagliano A, Germanò E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol. 2004 ; 14 (1). 39-47 (Pubitemid 38525952)
148. Bell JG, MacKinlay EE, Dick JR, et al. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids. 2004 ; 71: 201-204 (Pubitemid 39037633)
149. Bu B, Ashwood P, Harvey D, et al. Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins Leukot Essent Fatty Acids. 2006 ; 74: 215-221
150. Johnson CR, Handen BL, Zimmer M, et al. Polyunsaturated fatty acid supplementation in young children with autism. J Dev Phys Disabil. 2009 ; 22: 1-10
151. Politi P, Cena H, Comelli M, et al. Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res. 2008 ; 39: 682-685
152. Meiri G, Bichovsky Y, Belmaker PY. Omega-3 fatty acid treatment in autism. J Child Adolesc Psychopharmacol. 2009 ; 19 (4). 449-451
153. Meguid NA, Atta HM, Gouda AS, et al. Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem. 2008 ; 41: 1044-1048
154. PatrickLSalikR. Study report. Benefits of essential fatty acid supplementation on language and learning skills in children with autism and Asperger's syndrome. http://gapsaustralia.com.au/wpcontent/uploads/2010/03/ PatrickStudy05.pdf. Accessed February 28, 2011.
155. Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized placebo-controlled pilot study. Biol Psychiatry. 2007 ; 61: 551-553 (Pubitemid 46185334)
156. Schoene NW. Vitamin E and omega-3 fatty acids: effectors of platelet responsiveness. Nutrition. 2001 ; 17: 793-796 (Pubitemid 33001641)
157. Yehuda S, Rabinowitz S, Mostofsky PY. Mixture of essential fatty acids lowers test anxiety. Nutr Neurosci. 2005 ; 8: 265-267 (Pubitemid 43250407)
158. Canitano R, Scandurra V. Psychopharmacology in autism: an update. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35 (1). 18-28
159. Buydens-Branchey L, Branchey M, Hibbeln PY. Association between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog Neuropsychopharmacol Biol Psychiatry. 2008 ; 32: 568-575 (Pubitemid 351178978)
160. Fux M, Benjamin J, Nemets B. A placebo controlled cross over trial of adjunctive EPA in OCD. J Psychiatr Res. 2004 ; 38: 323-325 (Pubitemid 38299170)
161. Zeev K, Michael M, Ram K, et al. Possible deleterious effects of adjunctive omega-3 fatty acids in post traumatic stress disorder patients. Neuropsychiatr Dis Treat. 2005 ; 1: 187-190
162. Matsuoka Y, Nishi D, Yonemoto N, et al. Omega-3 fatty acids for secondary prevention of post traumatic stress disorder after accidental injury: an open-label pilot study. J Clin Psychopharmacol. 2010 ; 30 (2). 217-219
163. Jacobs MN, Santillo D, Johnston PA, et al. Organochlorine residues in fish oil dietary supplements: a comparison of industrial grade oils. Chemosphere. 1998 ; 37: 1709-1721 (Pubitemid 28480041)
164. Chiuchiolo AL, Dickhut AL, Cochran MA, et al. Persistant organic pollutants at the base of the antartic marine food web. Environ Sci Technol. 2004 ; 38 (13). 3551-3557 (Pubitemid 38879893)
165. EPA-823-R-04-005: What you need to know about mercury in fish and shellfish. 2004. http://www.fda.gov/Food/FoodSafety/Product-SpecificInformation/ Seafood/FoodbornePathogensContaminants/Methylmercury/ucm115662.htm. Accessed June 21, 2011.
166. BentSBertoglioKAshwoodP. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord. 2010;41:545-554; http://www.springerlink.com/content/gh8166v88110575l/fulltext.pdf. Accessed February 6, 2011.
167. Hilbert G, Lillemark L, Balchen S, et al. Reductions of organochlkorine contaminants from fish oil during refining. Chemosphere. 1998 ; 37: 1241-1252 (Pubitemid 28398583)